XML 19 R6.htm IDEA: XBRL DOCUMENT v3.23.2
CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Angi Inc.
IAC
Redeemable Noncontrolling Interests
Redeemable Noncontrolling Interests
Vivian Health
Total IAC Shareholders' Equity
Total IAC Shareholders' Equity
Angi Inc.
Total IAC Shareholders' Equity
IAC
Common Stock
Common Stock, $0.0001 par value
Common Stock
Class B common stock, $0.0001 par value
Additional Paid-in-Capital
Additional Paid-in-Capital
Angi Inc.
Retained Earnings (Accumulated Deficit)
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss)
Angi Inc.
Treasury Stock
Treasury Stock
IAC
Noncontrolling Interests
Noncontrolling Interests
Angi Inc.
Balance at beginning of period at Dec. 31, 2021       $ 18,741                              
Increase (Decrease) in Redeemable Noncontrolling Interests                                      
Net (loss) earnings       (2,387)                              
Other comprehensive loss       0                              
Distribution to and purchase of noncontrolling interests       (1,179)                              
Adjustment of noncontrolling interests to fair value       24,041                              
Issuance of Vivian Health preferred shares, net of fees, and the reclassification and creation of noncontrolling interest         $ (11,782)                            
Other       (26)                              
Balance at end of period at Jun. 30, 2022       27,408                              
Balance at beginning of period at Dec. 31, 2021 $ 7,748,960         $ 7,175,226     $ 8 $ 1 $ 6,265,669   $ 905,151 $ 4,397   $ 0   $ 573,734  
Balance at beginning of period (in shares) at Dec. 31, 2021                 83,922 5,789                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                      
Net (loss) earnings (1,113,905)         (1,104,928)             (1,104,928)         (8,977)  
Other comprehensive income, net of income taxes (18,093)         (17,250)               (17,250)       (843)  
Stock-based compensation expense 62,608         34,941         34,941             27,667  
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (14,810) $ (3,923)       (14,810) $ (4,101)       (14,810) $ (4,102)     $ 1       $ 178
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (in shares)                 210                    
Purchase of treasury stock   (8,144) $ (59,079)       (8,144) $ (59,079)       (8,144)         $ (59,079)    
Adjustment of noncontrolling interests to fair value (24,041)         (24,041)         (24,041)                
Adjustment to the liquidation value of Vivian Health preferred shares 54,700         11,526         11,526             43,174  
Other 890         890         890                
Balance at end of period at Jun. 30, 2022 6,625,163         5,990,230     $ 8 $ 1 6,261,929   (199,777) (12,852)   (59,079)   634,933  
Balance at end of period (in shares) at Jun. 30, 2022                 84,132 5,789                  
Balance at beginning of period at Mar. 31, 2022       27,817                              
Increase (Decrease) in Redeemable Noncontrolling Interests                                      
Net (loss) earnings       (2,353)                              
Distribution to and purchase of noncontrolling interests       (1,179)                              
Adjustment of noncontrolling interests to fair value       14,905                              
Issuance of Vivian Health preferred shares, net of fees, and the reclassification and creation of noncontrolling interest         $ (11,782)                            
Balance at end of period at Jun. 30, 2022       27,408                              
Balance at beginning of period at Mar. 31, 2022 7,500,917         6,919,455     $ 8 $ 1 6,249,328   669,353 765   0   581,462  
Balance at beginning of period (in shares) at Mar. 31, 2022                 84,075 5,789                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                      
Net (loss) earnings (873,046)         (869,130)             (869,130)         (3,916)  
Other comprehensive income, net of income taxes (14,392)         (13,616)               (13,616)       (776)  
Stock-based compensation expense 32,350         18,239         18,239             14,111  
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (798) (1,450)       (798) (2,328)       (798) (2,327)     (1)       878
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (in shares)                 57                    
Purchase of treasury stock     (59,079)         (59,079)                 (59,079)    
Adjustment of noncontrolling interests to fair value (14,905)         (14,905)         (14,905)                
Adjustment to the liquidation value of Vivian Health preferred shares 54,700         11,526         11,526             43,174  
Other 866         866         866                
Balance at end of period at Jun. 30, 2022 6,625,163         5,990,230     $ 8 $ 1 6,261,929   (199,777) (12,852)   (59,079)   634,933  
Balance at end of period (in shares) at Jun. 30, 2022                 84,132 5,789                  
Balance at beginning of period at Dec. 31, 2022 27,235     27,235                              
Increase (Decrease) in Redeemable Noncontrolling Interests                                      
Net (loss) earnings       (542)                              
Adjustment of noncontrolling interests to fair value       8,089                              
Other       (4)                              
Balance at end of period at Jun. 30, 2023 34,778     34,778                              
Balance at beginning of period at Dec. 31, 2022 6,572,534         5,931,614     $ 8 $ 1 6,295,080   (265,019) (13,133)   (85,323)   640,920  
Balance at beginning of period (in shares) at Dec. 31, 2022                 84,184 5,789                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                      
Net (loss) earnings 324,231         328,730             328,730         (4,499)  
Other comprehensive income, net of income taxes 6,720         6,227               6,227       493  
Stock-based compensation expense 61,265         36,127         36,127             25,138  
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (4,575) (4,113)       (4,575) (6,572)       (4,575) (6,574)     $ 2       2,459
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (in shares)                 176                    
Purchase of treasury stock   (3,397) (167,179)       (3,397) (167,179)       (3,397)         (167,179)    
Adjustment of noncontrolling interests to fair value (8,089)         (8,089)         (8,089)                
Adjustment to the liquidation value of Vivian Health preferred shares 0         3,689         3,689             (3,689)  
Other 105         133         133             (28)  
Balance at end of period at Jun. 30, 2023 6,777,502         6,116,708     $ 8 $ 1 6,312,394   63,711 (6,904)   (252,502)   660,794  
Balance at end of period (in shares) at Jun. 30, 2023                 84,360 5,789                  
Balance at beginning of period at Mar. 31, 2023       27,189                              
Increase (Decrease) in Redeemable Noncontrolling Interests                                      
Net (loss) earnings       (288)                              
Adjustment of noncontrolling interests to fair value       7,881                              
Other       (4)                              
Balance at end of period at Jun. 30, 2023 34,778     $ 34,778                              
Balance at beginning of period at Mar. 31, 2023 6,920,480         6,267,301     $ 8 $ 1 6,306,229   152,756 (14,641)   (177,052)   653,179  
Balance at beginning of period (in shares) at Mar. 31, 2023                 84,257 5,789                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                      
Net (loss) earnings (91,342)         (89,045)             (89,045)         (2,297)  
Other comprehensive income, net of income taxes 8,114         7,737               7,737       377  
Stock-based compensation expense 31,332         20,064         20,064             11,268  
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (2,725) (1,703)       (2,725) (1,875)       (2,725) (1,875)             $ 172
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (in shares)                 103                    
Purchase of treasury stock   $ (3,397) $ (75,450)       $ (3,397) $ (75,450)       $ (3,397)         $ (75,450)    
Adjustment of noncontrolling interests to fair value (7,881)         (7,881)         (7,881)                
Adjustment to the liquidation value of Vivian Health preferred shares 0         1,877         1,877             (1,877)  
Other 74         102         102             (28)  
Balance at end of period at Jun. 30, 2023 $ 6,777,502         $ 6,116,708     $ 8 $ 1 $ 6,312,394   $ 63,711 $ (6,904)   $ (252,502)   $ 660,794  
Balance at end of period (in shares) at Jun. 30, 2023                 84,360 5,789